Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 177-187

  Neves, Ana Rute ^a   Lúcio, Marlene ^a   Martins, Susana ^a,b   Lima, José Luís Costa ^a   Reis, Salette ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

Author keywords

Nanodelivery systems; Nanostructured lipid carriers; Polyphenol; Solid lipid nanoparticles

Indexed keywords

DRUG CARRIER; MIGLYOL; NANOPARTICLE; NANOSTRUCTURED LIPID CARRIER; POLYSORBATE 60; RESVERATROL; SOLID LIPID CETYL PALMITATE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; BODY TEMPERATURE; CONTROLLED RELEASE FORMULATION; CRYO SCANNING ELECTRON MICROSCOPY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG QUALITY; DRUG RELEASE; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; DYNAMIC LIGHT SCATTERING; ENTHALPY; GASTROINTESTINAL TRANSIT; LIGHT SCATTERING; NANODELIVERY SYSTEM; PHASE TRANSITION; SCANNING ELECTRON MICROSCOPY; SOLID STATE; SURFACE PROPERTY; ZETA POTENTIAL;

NANODELIVERY SYSTEMS; NANOSTRUCTURED LIPID CARRIERS; POLYPHENOL; SOLID LIPID NANOPARTICLES;

ANALYSIS OF VARIANCE; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG CARRIERS; DRUG STABILITY; LIPIDS; MODELS, BIOLOGICAL; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; STILBENES; TEMPERATURE;

VITACEAE;

EID: 84872351206     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S37840     Document Type: Article

References (34)

1. Neves AR, Lucio M, Lima JL, Reis S. Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug-delivery, and membrane interactions. Curr Med Chem. 2012;19(11):1663-1681.
2. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004;32(12):1377-1382.
3. Vitaglione P, Sforza S, Galaverna G, et al. Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res. 2005;49(5): 495-504.
4. Lu X, Ji C, Xu H, et al. Resveratrol-loaded polymeric micelles protect cells from Abeta-induced oxidative stress. Int J Pharm. 2009;375(1-2): 89-96.
5. Shi G, Rao L, Yu H, Xiang H, Yang H, Ji R. Stabilization and encapsulation of photosensitive resveratrol within yeast cell. Int J Pharm. 2008; 349(1-2):83-93.
6. Caddeo C, Teskac K, Sinico C, Kristl J. Effect of resveratrol incorporated in liposomes on proliferation and UV-B protection of cells. Int J Pharm. 2008;363(1-2):183-191.
7. Das S, Ng KY. Resveratrol-loaded calcium-pectinate beads: effects of formulation parameters on drug release and bead characteristics. J Pharm Sci. 2010;99(2):840-860.
8. Teskac K, Kristl J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm. 2010;390(1):61-69.
9. Shao J, Li X, Lu X, et al. Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels. Colloids Surf B Biointerfaces. 2009;72(1):40-47.
10. Hentschel A, Gramdorf S, Müller RH, Kurz T. Beta-carotene-loaded nanostructured lipid carriers. J Food Sci. 2008;73(2):N1-N6.
11. Muchow M, Maincent P, Muller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm. 2008;34(12):1394-1405.
12. Acosta E. Bioavailability of nanoparticles in nutrient and nutraceutical delivery. Curr Opin Colloid Interface Sci. 2009;14(1):3-15.
13. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177.
14. Freitas C, Müller RH. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm. 1999;47(2):125-132.
15. Jenning V, Thünemann AF, Gohla SH. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm. 2000;199(2):167-177.
16. Al-Haj N, Rasedee A. Solid lipid nanoparticles preparation and characterization. Int J Pharm. 2009;5(1):90-93.
17. Smith JR, Larson C, Campbell SA. Recent applications of SEM and AFM for assessing topography of metal and related coatings - a review. Transactions of the Institute of Metal Finishing. 2011;89(1):18-27.
18. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2-3): 165-196.
19. Dubes A, Parrot-Lopez H, Abdelwahed W, et al. Scanning electron microscopy and atomic force microscopy imaging of solid lipid nanoparticles derived from amphiphilic cyclodextrins. Eur J Pharm Biopharm. 2003;55(3):279-282.
20. Teeranachaideekul V, Boonme P, Souto EB, Müller RH, Junyaprasert VB. Influence of oil content on physicochemical properties and skin distribution of Nile red-loaded NLC. J Control Release. 2008;128(2): 134-141.
21. des Rieux A, Fievez V, Momtaz M, et al. Helodermin-loaded nanoparticles: characterization and transport across an in vitro model of the follicle-associated epithelium. J Control Release. 2007;118(3): 294-302.
22. Saupe A, Wissing SA, Lenk A, Schmidt C, Müller RH. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) - structural investigations on two different carrier systems. Biomed Mater Eng. 2005;15(5):393-402.
23. Komatsu H, Kitajima A, Okada S. Pharmaceutical characterization of commercially available intravenous fat emulsions: estimation of average particle size, size distribution and surface potential using photon correlation spectroscopy. Chem Pharm Bull (Tokyo). 1995;43(8): 1412-1415.
24. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47(1):3-19.
25. Schwarz C, Mehnert W, Lucks JS, Müller RH. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Control Release. 1994;30(1):83-96.
26. Pople PV, Singh KK. Development and evaluation of topical formulation containing solid lipid nanoparticles of vitamin A. AAPS Pharm Sci Tech. 2006;7(4):91.
27. Vivek K, Reddy H, Murthy RS. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. AAPS Pharm Sci Tech. 2007;8(4):E83.
28. Siekmann B, Westesen K. Thermoanalysis of the recrystallization process of melt-homogenized glyceride nanoparticles. Colloids Surf B Biointerfaces. 1994;3(3):159-175.
29. Westesen K, Siekmann B, Koch MH. Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction. Int J Pharm. 1993;93(1-3):189-199.
30. Ahlin P, Šentjurc M, Štrancar J, Kristl J. Location of lipophilic substances and ageing of solid lipid nanoparticles studied by EPR. STP Pharma Sciences. 2000;10(2):125-132.
31. Ahlin P, Kristl J, Pecar S, Štrancar J, Šentjurc M. The effect of lipophilicity of spin-labeled compounds on their distribution in solid lipid nanoparticle dispersions studied by electron paramagnetic resonance. J Pharm Sci. 2003;92(1):58-66.
32. Müller RH, Mehnert W, Lucks JS, et al. Solid lipid nanoparticles (SLN): an alternative colloidal carrier system for controlled drug-delivery. Eur J Pharm Biopharm. 1995;41(1):62-69.
33. Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2(3):289-300.
34. Torres D, Alonso MJ. Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloid Surf B Biointerfaces. 2003;27(2-3):159-168.